RxDoctor Payments Data

Sarah Gossett, NP

Nurse Practitioner · la Crosse, WINPI 1508105495

Payments from drug & device makers

$1,946in general payments, 2019–2025

Across 20 payments — averaging $97.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$843
  • Novo Nordisk$582
  • Sanofi-aventis U.S. LLC$158
  • Abbott$125
  • Insulet Corporation$125
  • Tandem Diabetes Care, Inc.$64
  • plus $49 from 1 others

What the payments were for

  • Food & beverage$1,946100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,946 in reported general payments places this provider in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$33,192
Medicare patients
172
Services billed
682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide235$288,183
MounjaroTirzepatide218$282,653
JardianceEmpagliflozin153$164,289
Humalog Kwikpen U-200Insulin Lispro64$103,946
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog105$77,570
TrulicityDulaglutide66$68,367
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/755$63,508
Fiasp FlextouchInsulin Aspart (Niacinamide)81$62,958
Tresiba Flextouch U-200Insulin Degludec63$62,848
Humulin R U-500 KwikpenInsulin Regular, Human31$39,850
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog47$25,782
Tresiba Flextouch U-100Insulin Degludec37$19,787
FiaspInsulin Aspart (Niacinamide)13$19,215
FarxigaDapagliflozin Propanediol12$19,120
Novolog FlexpenInsulin Aspart50$13,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Novolog$582$315,132272 claims
Sanofi-aventis U.S. LLCLantus$158$1,73923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in la Crosse

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →